24-hour Bronchodilation following a single dose of the novel β 2-agonist olodaterol in COPD

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 6, 2011, Pages 666-672

  van Noord, J A ^a   Smeets, J J ^a   Drenth, B M ^a   Rascher, J ^b   Pivovarova, A ^b   Hamilton, A L ^c   Cornelissen, P J G ^b  

^a Zuyderland Medical Centre   (Netherlands)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

Chronic obstructive pulmonary disease; Olodaterol; Once daily inhaled 2 agonist; Pharmacokinetics; Spirometry

Indexed keywords

OLODATEROL; PLACEBO; SALBUTAMOL;

ABSCESS; ADULT; AGED; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART PALPITATION; HEMOPTYSIS; HUMAN; INHALER; MALE; MUSCLE CRAMP; NAUSEA; OPEN STUDY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SHIVERING; SHOULDER PAIN; SIDE EFFECT; SINGLE DRUG DOSE; SPIROMETRY; TREMOR; URINARY EXCRETION; VOMITING;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BENZOXAZINES; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME FACTORS;

EID: 80955142812     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.07.006     Document Type: Article

References (28)

1. From the global strategy for the diagnosis, management and prevention of copd, global initiative for chronic obstructive lung disease (gold) update 2009, Available from, [accessed 25.01.10]. http://www.goldcopd.org.
2. Celli B.R., MacNee W. ATS/ERS task force, standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
3. Maesen F.P.V., Smeets J.J., Sledsens T.J.H., Wald F.D.M., Cornelissen P.J.G. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease. Eur Respir J 1995, 8:1506-1513.
4. van Noord J.A., Bantje T.A., Eland M.E., Korducki L., Cornelissen P.J.G. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. the Dutch tiotropium study group. Thorax 2000, 55:289-294.
5. Ulrik C.S. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax 1995, 50:750-754.
6. Boyd G., Morice A.H., Pounsford J.C., Siebert M., Peslin N., Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997, 10:815-821.
7. Cazzola M., Matera M.G., Santangelo G., Vinciguerra A., Rossi F., D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995, 89:357-362.
8. Rossi A., Kristufek P., Levine B.E., Thomson M.H., Till D., Kottakis J., et al. Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002, 121:1058-1069.
9. Fitzgerald M.F., Fox J.C. Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapy. Drug Discov Today 2007, 12:472-478.
10. Cazzola M., Matera M.G. Emerging inhaled bronchodilators: an update. Eur Respir J 2009, 34:757-769.
11. 2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett 2010, 20:1410-1414.
12. 2-adrenoceptor agonist exerting a 24-hour long duration of action in preclinical models. J Pharmacol Exp Ther 2010, 334:53-62.
13. 2-agonist, in patients with mild asthmatics. J Allergy Clin Immunol 2010, 124:1217-1221.
14. Celli B.R., Snider G.L., Heffner J., Tiep B., Ziment I., Make B., et al. Standard for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995, 152:S77-S120.
15. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., Yernault J.-C. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Eur Respir J 1993, 6(Suppl 16):5-40.
16. ICH E14: Note for guidance on the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (CHMP/ICH/2/04), 25 May 2005.
17. Standardization of spirometry - 1994 update. Am J Respir Crit Care Med 1995, 152:1107-1136. American Thoracic Society.
18. Calverley P.M.A., Lee A., Towse L., van Noord J.A., Witek T.J., Kesten S. Effect of tiotropium on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003, 58:855-860.
19. van Noord J.A., Aumann J.L., Janssens E., Verhaert J., Smeets J.J., Mueller A., et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129:509-517.
20. Cazzola M., Proietto A., Matera M.G. Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs of Today 2010, 46:139-150.
21. Bourbeau J., Bartlett S.J. Patient adherence in COPD. Thorax 2008, 63:831-838.
22. Beeh K.M., Beier J. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 2010, 27:150-159.
23. Bateman E.D. Improving inhaler use in COPD and the role of patient preference. Eur Respir Rev 2005, 14:85-88.
24. Newman S.P. Inhaler treatment options in COPD. Eur Respir Rev 2005, 14:102-108.
25. ® Soft Mist™ Inhaler. Int J COPD 2009, 4:381-390.
26. ® Soft Mist™ Inhaler and pressurized metered dose inhalers. J Aerosol Med 2005, 18:S273-S282.
27. ® Soft Mist™ Inhaler compared to deposition by metered dose inhaler or by Turbohaler dry powder inhaler. J Aerosol Med 2005, 18:S264-S272.
28. ® Soft Mist™ Inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis 2008, 3:763-770.